Matthew Newbold, OD
Optometrist · Las Cruces, NMNPI 1083283642
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Alcon at 32.7% of the total. Reporting peaked in 2024 at $744 and has fallen 61.8% since, to $284 in 2025.
Across 41 payments — averaging $30.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$405
- Dompe US, Inc.$246
- Tarsus Pharmaceuticals, Inc.$241
- LKC Technologies, Inc.$82
- Bausch & Lomb Americas Inc.$80
- Amgen$53
- plus $132 from 6 others
What the payments were for
- Food & beverage$1,240100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 12 | $405 |
| Dompe US, Inc. | 7 | $246 |
| Tarsus Pharmaceuticals, Inc. | 7 | $241 |
| LKC Technologies, Inc. | 2 | $82 |
| Bausch & Lomb Americas Inc. | 4 | $80 |
| Amgen | 3 | $53 |
| AbbVie | 1 | $33 |
| Novartis | 1 | $25 |
| Oyster Point Pharma, Inc. | 1 | $24 |
| Biotissue Holdings Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $16 |
| Rxsight Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,240 in reported general payments places this provider in the 75th percentile of 228 optometrist providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 27 | $1,440,790 |
| XdemvyLotilaner | 103 | $194,554 |
| LumiganBimatoprost | 100 | $63,155 |
| XiidraLifitegrast | 22 | $36,830 |
| TyrvayaVarenicline Tartrate | 28 | $36,747 |
| RestasisCyclosporine | 21 | $28,975 |
| MieboPerfluorohexyloctane/Pf | 31 | $27,898 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 58 | $10,070 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $6,679 |
| Latanoprost | 452 | $6,116 |
| TobradexTobramycin/Dexamethasone | 15 | $4,039 |
| Prednisolone Acetate | 57 | $2,819 |
| Brimonidine Tartrate | 95 | $2,292 |
| Loteprednol Etabonate | 14 | $2,043 |
| Travoprost | 11 | $1,408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $246 | $1,440,79027 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $241 | $194,554103 claims |
| AbbVieLumigan, Restasis, Combigan | $33 | $98,808140 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $80 | $64,72853 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $24 | $36,74728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 228 optometrist providers in New Mexico.
Other optometrist in Las Cruces
- Adrian TenorioLas Cruces$3K
- Angela MorganLas Cruces$3K
- Jennifer MurrayLas Cruces$2K
- Carla WendlerLas Cruces$2K
- Thomas KunzLas Cruces$1K
- Elisabeth HottelLas Cruces$979
- Keith BarkerClovis$52K
- Elysia IsonShiprock$37K
- David BabingtonAlbuquerque$8K
- David ViseSanta Fe$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.